 |
 |
|
Do you know what deals have influenced Pfizer's business strategy to-date?What effect has the sanofi-aventis merger had on its deal making?PharmaDeals® Spotlight Reports detail the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005. If you are looking to partner with big pharma, these reports are crucial to your deal making strategy. Choose from the following titles: Deal Making Spotlight on: Pfizer, sanofi-aventis, GlaxoSmithKline, Johnson & Johnson and Novartis. Special pre-publication priceThese reports are due to be published in February 2006. Order by the 31st January 2006 and be eligible for the special pre-publication price of £299 / €449 / US$508 instead of the normal price of £350 / €525 / US$595. Buy 3 reports for £850 / €1275 / US$1445 or you can order all 5 reports for £1250 / €1875 / US$2125. Download an order form |
||
 |
 |
 |
Market News and TrendsDuring November 2005 a total of 25 deals were made in the drug delivery sector. These included a relatively high number of agreements relating to one particular class of technologies: those designed for transdermal drug delivery. These transactions centred upon a variety of products, including an insulin patch for diabetics and an ultrasonic skin-permeation device with a dengue vaccine. Also of note in November 2005 was a deal of great potential value between Johnson & Johnson and Abbott Laboratories. Read more... |
||
|
|
||
Featured ArticleLiquid Transdermal Drug Delivery: The State of the TDS® ArtTo date, transdermal delivery has been effective in delivering only a very few drugs due to difficulties in moving larger, and chemically non-compatible, molecules across the skin's biologically-active barrier. More recently, alternative approaches have been attempted to expand possibilities, employing various devices and modalities to breach what is designed to keep the outside out and the inside in. Until now a truly flexible, convenient enabler of transdermal dosing has been lacking. In this article, Kenneth Kirby, President of Transdermal Technologies, Inc., discusses developments in this mode of delivery with its patented TDS® liquid spray-on technology. Read more... |
 |
||
|
|
||
 |
Company ProfilesAveva, Dermisonics, Forte, Novagali |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity Product to Prevent Restenosis Administrative route - Drug eluting stent Indication - Restenosis Licence code LO-1105-08 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Companies Spring / Summer 2006For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail ddr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddr@pharmamail.biz with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail ddr@pharmamail.biz